EDEM Antibodies

Santa Cruz Biotechnology features a diverse variety of EDEM Antibodies for studying the endoplasmic reticulum-associated degradation (ERAD) pathway. EDEM Antibodies are compatible with multiple research techniques, including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). EDEM (ER degradation-enhancing alpha-mannosidase-like protein) plays a crucial role in the quality control of glycoproteins within the endoplasmic reticulum, ensuring that misfolded proteins are efficiently recognized and targeted for degradation. The ERAD pathway is vital for maintaining cellular homeostasis and preventing the accumulation of dysfunctional proteins, which can lead to various diseases. Understanding EDEM function is essential for elucidating the mechanisms of protein folding and degradation in health and disease. Research into EDEM has revealed significant implications for neurodegenerative disorders, cancer, and other pathological conditions. Investigating EDEM's role in protein quality control continues to yield important insights into cellular stress responses and disease mechanisms. EDEM monoclonal antibodies from Santa Cruz Biotechnology enable researchers worldwide to advance scientific understanding of protein quality control mechanisms and their impact on human health.